Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 2:46 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 16,122 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorder Clear all
Completed Not applicable Interventional

Screening Mammography and Latinas: A Multilevel Intervention

NCT02010008
View directory record Official record
Conditions
Breast Cancer
Interventions
Motivational Interviewing Intervention
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Nov 1, 2026, 2:46 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study of D-Methadone in Patients With Chronic Pain

NCT00588640
View directory record Official record
Conditions
Pain, Bladder Cancer, Breast Cancer, CNS Cancer, Colon Cancer, Esophageal Cancer, Pancreatic Cancer, Prostate Cancer, Uterine Cancer, Head and Neck Cancer, Eye Cancer, Otorhinolaryngologic Neoplasms
Interventions
D-methadone, placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Nov 1, 2026, 2:46 AM EST
Terminated Phase 2 Interventional Results available

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

NCT02855268
View directory record Official record
Conditions
Alport Syndrome
Interventions
lademirsen (SAR339375), Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Minneapolis, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Nov 1, 2026, 2:46 AM EST
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

NCT01449591
View directory record Official record
Conditions
Erythemato-telangiectatic Rosacea
Interventions
BFH772 1% ointment, Vehicle ointment, Noritate® 1% cream
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Hot Springs, Arkansas • Ann Arbor, Michigan • Paramus, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Nov 1, 2026, 2:46 AM EST
Completed Phase 2 Interventional Results available

Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris

NCT03573518
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BTX 1503, Vehicle
Drug
Lead sponsor
Botanix Pharmaceuticals
Industry
Eligibility
12 Years to 40 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
25
States / cities
Little Rock, Arkansas • Encino, California • Murrieta, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Nov 1, 2026, 2:46 AM EST
Recruiting Not applicable Interventional

Fast-Her: Fasting Effects on Breast Cancer Treatment

NCT07624617
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Normal Eating, Prolonged Fasting
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 1, 2026, 2:46 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status

NCT01629940
View directory record Official record
Conditions
X-linked Hypohidrotic Ectodermal Dysplasia, Hypohidrotic Ectodermal Dysplasia
Interventions
Not listed
Lead sponsor
Edimer Pharmaceuticals
Industry
Eligibility
Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Nov 1, 2026, 2:46 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis

NCT00723489
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Live Yellow Fever Vaccine (YFV-17D), YFV-17D Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
27 Years to 43 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
San Diego, California • Denver, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Nov 1, 2026, 2:46 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Morbidity After Diagnosis and Treatment of Breast Cancer Patients

NCT00027118
View directory record Official record
Conditions
Breast Cancer, Shoulder, Lymphedema, Fatigue
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 85 Years
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Nov 1, 2026, 2:46 AM EST
Completed Phase 4 Interventional Results available

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

NCT01735955
View directory record Official record
Conditions
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
Interventions
Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
2
States / cities
Albany, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Nov 1, 2026, 2:46 AM EST
Completed Not applicable Interventional

Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery

NCT04233385
View directory record Official record
Conditions
Breast Cancer, Mastectomy; Lymphedema, Pain, Shoulder, Mobility Limitation
Interventions
Myofascial Massage, Light Touch
Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Nov 1, 2026, 2:46 AM EST
Completed Phase 3 Interventional Results available

Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.

NCT02978508
View directory record Official record
Conditions
Scabies
Interventions
Permethrin Cream, 5%, Elimite
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Richland, Washington
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Nov 1, 2026, 2:46 AM EST
Completed No phase listed Observational

Psychosocial Impact of Cancer-Related Female Infertility

NCT00386217
View directory record Official record
Conditions
Hodgkin's Disease, Cervical Cancer, Breast Cancer, Lymphoma
Interventions
Telephone Survey
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
14 Years and older · Female only
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Nov 1, 2026, 2:46 AM EST
Completed Phase 1Phase 2 Interventional

A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)

NCT00932074
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
KP-413 Ointment
Drug
Lead sponsor
Kaken Pharmaceutical
Industry
Eligibility
18 Years to 64 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Clinton Twp., Michigan • Portland, Oregon • Austin, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Nov 1, 2026, 2:46 AM EST
Completed Phase 1 Interventional

A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies

NCT01844674
View directory record Official record
Conditions
Malignant Melanoma, Neoplasms
Interventions
Tizanidine, Vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Pleasant Hill, California • Detroit, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Nov 1, 2026, 2:46 AM EST
Completed Phase 4 Interventional Results available

Pressure Ulcer Healing With Microcyn

NCT02001558
View directory record Official record
Conditions
Pressure Ulcer, Spinal Cord Injuries
Interventions
Microcyn, Sterile saline
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Nov 1, 2026, 2:46 AM EST
Not listed Not applicable Interventional

Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis

NCT06074315
View directory record Official record
Conditions
Distal Lateral Subungual Onychomycosis, Onychomycosis
Interventions
Nail Genesis DLSO Product, Nail Genesis DLSO Product (vehicle only)
Device
Lead sponsor
Nail Genesis LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Fayetteville, Arkansas • Montclair, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Nov 1, 2026, 2:46 AM EST
Completed Phase 2 Interventional Results available

An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)

NCT02776735
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Sarilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Nov 1, 2026, 2:46 AM EST
Completed Not applicable Interventional

Marfan Syndrome Moderate Exercise Pilot

NCT04641325
View directory record Official record
Conditions
Marfan Syndrome
Interventions
Exercise Intervention Group
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Nov 1, 2026, 2:46 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Part II: Exercise in Hispanic Breast Cancer Survivors

NCT01504789
View directory record Official record
Conditions
Breast Cancer
Interventions
Baseline Fitness Test, Questionnaires, Individualized Exercise Program, Written Materials
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 1, 2026, 2:46 AM EST
Completed Phase 1Phase 2 Interventional

Anti-CD20 in Systemic Lupus Erythematosus

NCT00036491
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
3
States / cities
Denver, Colorado • Rochester, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Nov 1, 2026, 2:46 AM EST
Completed Early Phase 1 Interventional

Searching for Persistence of Infection in Lyme Disease

NCT01143558
View directory record Official record
Conditions
Lyme Disease
Interventions
Lyme Disease Xenodiagnosis
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
New Haven, Connecticut • Bethesda, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 1, 2026, 2:46 AM EST
Completed Not applicable Interventional

Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors

NCT02150148
View directory record Official record
Conditions
Cancer
Interventions
Experimental: Mentored Gardening Intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Nov 1, 2026, 2:46 AM EST
Completed No phase listed Observational

MRI for Screening and Monitoring Scleroderma ILD

NCT05204355
View directory record Official record
Conditions
Scleroderma
Interventions
MRI, Hyperpolarized Xe129, HRCT
Diagnostic Test · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 1, 2026, 2:46 AM EST